StockNews.com started coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research report released on Wednesday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Performance
Titan Pharmaceuticals stock opened at $4.79 on Wednesday. The company’s 50-day moving average price is $5.66 and its 200-day moving average price is $6.12. Titan Pharmaceuticals has a twelve month low of $4.24 and a twelve month high of $14.80.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last issued its quarterly earnings data on Thursday, August 15th. The specialty pharmaceutical company reported ($2.29) earnings per share for the quarter.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Featured Stories
- Five stocks we like better than Titan Pharmaceuticals
- How to Most Effectively Use the MarketBeat Earnings Screener
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- Profitably Trade Stocks at 52-Week Highs
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
- Short Selling: How to Short a Stock
- MarketBeat Week in Review – 10/14 – 10/18
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
